Evidence map›Paper›PMID 31890432›Full record

ArticleCureus2019

Immune-mediated Colitis from Dual Checkpoint Inhibitors.

Nishanth Thalambedu, Yasir Khan, Qian Zhang, Shristi Khanal, Ammar Ashfaq

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Cureus, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Nishanth ThalambeduInternal Medicine, Abington Hospital - Jefferson Health, Abington, USA.
Yasir KhanInternal Medicine, Abington Hospital - Jefferson Health, Abington, USA.
Qian ZhangInternal Medicine, Abington Hospital, Jefferson Health, Abington, USA.
Shristi KhanalInternal Medicine, Abington Hospital-Jefferson Health, Abington, USA.
Ammar AshfaqInternal Medicine, Abington Hospital-Jefferson Health, Abington, USA.
Thomas Jefferson University Hospital · USAbington Memorial Hospital · USJefferson Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma is a deadly disease with immunotherapy treatment options that emerged in the last few years and have changed the disease outcome. However, it is associated with immune-related toxic effects despite improving survival. We present the case of a 53-year-old woman who had two weeks of diarrhea after she was treated with dual immunotherapy agents for her advanced melanoma. The final workup revealed pancolitis, possibly due to immunotherapy adverse effects. Initial conservative treatment, unfortunately, did not lead to a clinical improvement until a steroid was introduced. We are reporting this case to alert our fellow physicians about the immune-mediated toxicities of the relatively new checkpoint inhibitors.

Indexed as

colitisimmune-related adverse eventsimmunotherapymelanoma

Identifiers

PMID31890432
PMCPMC6935326
OpenAlexW2989639797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.